進行期パーキンソン病の日本人成人患者におけるABBV-951皮下注入による疾患活動性および有害事象の変化を評価する観察研究

基本情報

NCT ID

NCT05916157

ステータス

募集中

試験のフェーズ

-

試験タイプ

観察

目標被験者数

250

治験依頼者名

AbbVie

概要

Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to assess how safe and effective ABBV-951 is in treating participants with Parkinson's disease in real world setting. ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan. Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.

対象疾患

依頼者（Sponsor）

実施施設 (16)